Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial.
暂无分享,去创建一个
A. Garden | S. Lippman | W. Hong | J. Lee | A. El‐Naggar | L. Byers | V. Papadimitrakopoulou | L. Ginsberg | W. William | M. Kies | J. Lewin | F. C. Holsinger | Heather Y. Lin | E. Massarelli | B. Glisson | K. Gillaspy | A. El-Naggar | F. Holsinger | J. Lee | W. Hong | Adel K. El-Naggar | Heather Y. Lin | William N. William | W. K. Hong | Scott M. Lippman | J. J. Lee | F. Holsinger | Lawrence E. Ginsberg | Jan S. Lewin | K. A. Gillaspy | W. William | F. C. Holsinger
[1] C. Chung,et al. Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] F. Hilgers,et al. First‐year quality of life assessment of an intra‐arterial (RADPLAT) versus intravenous chemoradiation phase III trial , 2009, Head & neck.
[3] Dong M Shin,et al. Recent advances in head and neck cancer. , 2008, The New England journal of medicine.
[4] C. Bokemeyer,et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.
[5] A. Garden,et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] C. Tsien,et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] W. Westra,et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. , 2008, Journal of the National Cancer Institute.
[8] A. Cmelak,et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. , 2008, Journal of the National Cancer Institute.
[9] E. Vokes,et al. Aspiration in chemoradiated patients with head and neck cancer. , 2007, Archives of otolaryngology--head & neck surgery.
[10] T. Gorlia,et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. , 2007, The New England journal of medicine.
[11] A. Markoe,et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. , 2007, The New England journal of medicine.
[12] Jeremy MG Taylor,et al. Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking. , 2007, International journal of radiation oncology, biology, physics.
[13] S. Spencer,et al. Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG, E2303) , 2007 .
[14] M. Leblanc,et al. Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer? , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Christopher U. Jones,et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.
[16] J. Holland,et al. Swallowing Function after Chemoradiation for Advanced Stage Oropharyngeal Cancer , 2004, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[17] J. Carles,et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] A. Rademaker,et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] E. Vokes,et al. The expanding role of systemic therapy in head and neck cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] A. Garden,et al. Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma? , 2004, Cancer.
[21] A. Garden. Where are the at-risk cervical nodes? , 2004, International journal of radiation oncology, biology, physics.
[22] Ellen B. Roecker,et al. A penetration-aspiration scale , 2004, Dysphagia.
[23] A. Rademaker,et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Bourhis,et al. End points for new agents in induction chemotherapy for locally advanced head and neck cancers. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] L. Dawson,et al. Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. , 2002, International journal of radiation oncology, biology, physics.
[26] J. Pignon,et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta analysis of chemotherapy on head and neck cancer , 2001 .
[27] J. Bourhis,et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data , 2000, The Lancet.
[28] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[29] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[30] A. Garden,et al. Radiotherapy for Head and Neck Cancers: Indications and Techniques , 1993 .
[31] B W Brown,et al. Concomitant boost radiotherapy schedules in the treatment of carcinoma of the oropharynx and nasopharynx. , 1990, International journal of radiation oncology, biology, physics.
[32] M. List,et al. A performance status scale for head and neck cancer patients , 1990, Cancer.
[33] J. Logemann,et al. Evaluation and treatment of swallowing disorders , 1983 .